Business Context and Reporting Period
Company: Summit Therapeutics plc (formerly Summit Corporation plc)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended January 31, 2015
Business Overview: Summit Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines for Duchenne muscular dystrophy (DMD) and Clostridium difficile infection (CDI). The company has no approved products and has incurred significant losses since inception. Its lead product candidates are SMT C1100 (for DMD) and SMT19969 (for CDI).
Key Financial Metrics
| Metric | 2015 (USD) | 2015 (GBP) | 2014 (GBP) |
|---|---|---|---|
| Other Operating Income | $3,228 | £2,148 | £1,844 |
| Operating Loss | $(19,100) | £(12,711) | £(6,709) |
| Net Loss | $(17,074) | £(11,363) | £(6,093) |
| Loss Per Share (Basic/Diluted) | $(0.44) | £(0.29) | £(0.30) |
| Cash and Cash Equivalents | $16,927 | £11,265 | £2,030 |
| Total Assets | $29,146 | £19,396 | £7,295 |
| Total Equity | $22,488 | £14,966 | £4,762 |
| Accumulated Losses | N/A | £(30,255) | £(45,183) |
Note: USD figures are translated at the rate of £1.00 = $1.5026 as of January 30, 2015. The filing does not provide specific revenue figures as the company has no commercial product sales; "Other operating income" consists of grants and funding.
Material Changes vs. Prior Period
- Increased Operating Loss: Operating loss increased by 89.5% (from £6.7 million to £12.7 million) and net loss increased by 86.5% (from £6.1 million to £11.4 million) compared to the prior year.
- R&D Expense Growth: Research and development expenses rose 57.6% to £10.4 million, driven by increased spending on DMD and CDI clinical programs, including Phase 1b and Phase 2 trials.
- G&A Expense Surge: General and administrative expenses increased 128.7% to £4.4 million, largely due to cash infusion milestone payments to patient advocacy groups, increased staffing, and share-based compensation.
- Liquidity Improvement: Cash and cash equivalents increased significantly from £2.0 million to £11.3 million, primarily due to a £20.5 million equity raise in March 2014 and a subsequent $39.3 million IPO in March 2015 (post-year-end).
- Share Capital Reorganization: The company completed a share consolidation, subdivision, and capital reduction in 2014, which reduced the accumulated deficit on the balance sheet by approximately £13.0 million.
Guidance, Outlook, and Risks
Outlook and Guidance
- Cash Runway: Management believes existing cash plus IPO proceeds will fund operations through the first half of 2016.
- Clinical Milestones:
- SMT C1100 (DMD): Top-line results from the Phase 1b modified diet trial are expected in Q3 2015. If successful, an open-label Phase 2 and a larger multinational Phase 2 trial are planned.
- SMT19969 (CDI): Top-line results from the ongoing Phase 2 proof-of-concept trial are expected in the second half of 2015. An exploratory Phase 2 trial comparing SMT19969 to fidaxomicin is also underway.
- Capital Needs: The company expects to incur significant expenses for several years and will require additional financing to complete development and commercialization.
Key Risks and Contingencies
- Development Risk: High risk of failure in clinical trials. Previous trials of a prior formulation of SMT C1100 by BioMarin failed to achieve therapeutic effect, though Summit has since modified the formulation and dosing strategy.
- Regulatory Uncertainty: No definitive guidance exists from regulators on the primary endpoint for DMD trials (Six Minute Walk Test), creating uncertainty in trial design and approval pathways.
- Financial Risk: The company has never generated revenue from product sales and relies on equity offerings, grants, and collaborations. Failure to raise capital could force delays or termination of programs.
- Intellectual Property: SMT19969 lacks composition-of-matter patent protection for its active ingredient, relying instead on method-of-treatment patents, which are harder to enforce against off-label use.
- Third-Party Dependence: Reliance on third-party manufacturers for clinical and commercial supply and contract research organizations for clinical trials.
Investor Verification Checklist
- Cash Burn Rate: Verify the accuracy of the "first half of 2016" runway estimate given the significant increase in operating expenses.
- Clinical Trial Results: Monitor the Q3 2015 results of the SMT C1100 Phase 1b modified diet trial and the H2 2015 results of the SMT19969 Phase 2 trial as critical value drivers.
- Grant Obligations: Review the terms of funding agreements with the Wellcome Trust, Innovate UK, and patient advocacy groups (MDA, DPF) regarding revenue sharing and milestone payments upon commercialization.
- Patent Portfolio: Assess the strength of the patent portfolio, specifically the lack of composition-of-matter protection for SMT19969 and the reliance on method-of-treatment claims.
- Share Dilution: Evaluate the impact of the March 2015 IPO and potential future equity raises on existing shareholder ownership.